The Organization
What's happening at Entrada Therapeutics? Entrada is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary and versatile approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. Our lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy (DMD) who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered with Vertex Pharmaceuticals to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1 (DM1).
2026 represents a catalyst-rich period for Entrada. We expect multiple clinical data readouts as we advance several DMD programs across the U.K., EU, and U.S. By year-end 2026, we anticipate four clinical-stage programs in our DMD franchise (ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51). These programs are complemented by the ongoing clinical progress of our DM1 collaboration with Vertex (VX-670).
We are a tight-knit team of experts and leaders in both therapeutic development and rare diseases and are excited to grow and attract colleagues who are ready to join a high-energy, dedicated team that likes to get things done and dramatically improve the lives of patients and their families.
The Perfect Addition to Our Team
You are patient focused and excited about the opportunity to help support and develop the Clinical Operations organization at Entrada. You enjoy a fast-paced environment and juggling competing priorities. You follow up and follow through, connecting problems with solutions efficiently. You work successfully in a team environment with strong interpersonal skills to effectively build working relationships inside and outside the company.
The Opportunity
This individual will assist the clinical operations team in the day-to-day operations, study start up and set-up, execution, and closeout of assigned trials. The individual is accountable to the clinical trial team for the support of trial execution and works collaboratively with cross-functional team members and vendors to ensure proper set-up of trial processes and plans to execute the protocol in accordance with established SOPs and standards.
Responsibilities
Support the day-to-day operations of assigned trials to ensure completion per established project team goals and objectives in compliance with ICH/GCP guidelines, from study start-up to close-out.
Provides accurate and up-to date clinical trial information within relevant tracking tools and provides regular updates of trial progression to the clinical trial team, including those related to protocol deviations, adverse events, and site personnel trainings.
Contribute to the development of trial related plans and manuals.
Ensures timely maintenance of the TMF, filing and reconciliation according to regulatory guidance and internal SOPs.
Participates and ensures appropriate documentation of clinical team meetings, including meeting minutes, agendas, and action items.
Manage vendor POs and trial payments (including budget reconciliation), including invoice review and approval.
Support the set-up and management of clinical trial supplies and biosample management where needed (drug product, ancillary and other).
Assist in external training activities (suppliers, clinical sites etc.).
Assist in the management of trial completion activities, including data review, database lock and trial closeout.
The Necessities
At Entrada, our passion for science, our devotion to patients and our values drives our behavior:
Humanity - We genuinely care about patients and about one another.
Tenacity - We are relentless and persistent in the pursuit of developing therapies for patients.
Creativity - We are creative problem solvers.
Collaboration - We are more than the sum of our parts.
Curiosity - We have a growth mindset and push conventional thought and theory.
To thrive on our team, you will need to come with:
BA/BS degree with at least 2+ years of relevant experience in clinical operations working at a biotech or pharmaceutical company.
Strong understanding of clinical trial operations, including all phases from study start-up to close-out.
Ability to work independently and take initiative on projects under minimal supervision.
General working knowledge of drug development and ICH/GCP guidelines is required.
Previous CRO or vendor management experience preferred.
Excellent interpersonal, written, administrative, and computer skills.
Excellent verbal and written communication skills with a strong attention for detail.
Ability to travel approximately 5% of the time, as determined by the needs of the business.
This role is a long-term contract position that follows a remote working model, requiring monthly or quarterly travel to the Entrada Therapeutics Headquarters in Boston, MA.
Equal Opportunity Employer
Entrada Therapeutics is an equal opportunity employer. Qualified candidates will receive consideration for employment without regard to race, color, religion, national origin, gender, sexual orientation, gender identity or expression, age, mental or physical disability, and genetic information, marital status, citizenship status, military status, protected veteran status or any other category protected by law.
Third Party Staffing Agencies
Entrada does not accept unsolicited resumes from any source other than directly from candidates. For the protection of all parties involved in the recruiting process, resumes will only be accepted from recruiters/agencies if a signed agreement is in place at the inception of the recruiting effort and authorized for a specified position. Unsolicited resumes sent to Entrada from recruiters/agencies do not constitute any type of relationship between the recruiter/agency and Entrada and do not obligate Entrada to pay fees if we hire from those resumes.
Privacy Statement
Entrada Therapeutics, Inc. (the “Entrada,” “we,” “us,” or “our”) respects your privacy and we want you to be familiar with how we collect, use, share, or otherwise process, your Personal Information. Please reference our privacy statement here to understand how and when your data is being used.
Entrada Therapeutics is a clinical-stage biopharmaceutical company developing a new class of genetic medicines designed to engage intracellular targets previously considered inaccessible. The company is advancing a robust portfolio of oligonucleotide programs for the treatment of neuromuscular and inherited retinal diseases, with lead programs targeting Duchenne muscular dystrophy (DMD) variants amenable to exon skipping. Entrada has partnered with Vertex Pharmaceuticals on VX-670, a clinical-stage program for myotonic dystrophy type 1 (DM1). The company expects a catalyst-rich 2026 with multiple clinical data readouts and four DMD programs anticipated to reach clinical stage by year-end.
